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Abstract
Objectives: The aim of the study was to find evidence of SARS-CoV-2 infection
in UK cats.
Design: Tissue samples were tested for SARS-CoV-2 antigen using
immunofluorescence and for viral RNA by in situ hybridisation. A set of
387 oropharyngeal swabs that had been submitted for routine respiratory
pathogen testing was tested for SARS-CoV-2 RNA using reverse transcriptase
quantitative PCR.
Results: Lung tissue collected post-mortem from cat 1 tested positive for both
SARS-CoV-2 nucleocapsid antigen and RNA. SARS-CoV-2 RNA was detected
in an oropharyngeal swab collected from cat 2 that presented with rhinitis
and conjunctivitis. High throughput sequencing of the viral genome revealed
five single nucleotide polymorphisms (SNPs) compared to the nearest UK
human SARS-CoV-2 sequence, and this human virus contained eight SNPs
compared to the original Wuhan-Hu-1 reference sequence. An analysis of the
viral genome of cat 2 together with nine other feline-derived SARS-CoV-2
sequences from around the world revealed no shared cat-specific mutations.
Conclusions: These findings indicate that human-to-cat transmission of
SARS-CoV-2 occurred during the COVID-19 pandemic in the UK, with the
infected cats developing mild or severe respiratory disease. Given the abil-
ity of the new coronavirus to infect different species, it will be important to
monitor for human-to-cat, cat-to-cat and cat-to-human transmission.
K E Y W O R D S
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INTRODUCTION
SARS-CoV-2 belongs to the same species (severe acute
respiratory syndrome-related coronavirus) as the coro-
navirus responsible for the 2003 SARS epidemic. It
emerged in December 2019, most likely from a bat
reservoir in China, although a role for an inter-
mediate species cannot be discounted.1,2 During
the current COVID-19 pandemic, naturally occurring
SARS-CoV-2 infections linked to transmission from
humans have been reported in domestic cats,3,4 non-
domestic cats,5 dogs6 and mink.7 In addition, in
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vivo experiments have shown that while cats, fer-
rets and hamsters are susceptible to SARS-CoV-2
infection, ducks, chickens and pigs are apparently
not susceptible.8,9 Cat-to-cat transmission has been
demonstrated experimentally,8,10 but the significance
of SARS-CoV-2 as a feline pathogen, as well as its
reverse zoonotic potential, remains poorly under-
stood. If SARS-CoV-2 were to establish new animal
reservoirs, this could have implications for future
emergence in humans.
At present, there is no evidence of cat-to-human
transmission or that cats, dogs or other domestic
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animals play any appreciable role in the epidemiol-
ogy of human infections with SARS-CoV-2.11 However,
although the pandemic is currently driven by human-
to-human transmission, it is important to address
whether domestic animals are susceptible to disease
or pose any risk to humans, particularly those indi-
viduals who are more vulnerable to severe disease.
Cats often live very closely with their owners, lick-
ing their hands or faces, sometimes sleeping on or in
their beds. There could also be risks associated with
washing the cats’ food and water bowls and cleaning
out litter boxes. Domestic animals could also act as
a viral reservoir, allowing continued transmission of
the virus, even when R < 1 in the human population.
Recent reports from Dutch mink farms of both mink-
to-cat and mink-to-human transmission of the virus
provide support for this scenario.7,12 We used a range
of laboratory techniques to show that two domestic
cats from households with suspected cases of COVID-
19 and which displayed either mild or severe respi-
ratory disease were infected with SARS-CoV-2. These
findings confirm that human-to-cat transmission of
SARS-CoV-2 occurs and can be associated with signs
of respiratory disease in cats.
MATERIALS AND METHODS
Samples
Sections of lung tissue were collected post-mortem
from cat 1, placed in virus transport medium (VTM)
and stored at −80◦C on 22 April 2020; on 10 June 2020
the VTM was removed, and RNAlater was added. Lung
tissue was also stored in formalin from 22 April until 8
June, when it was processed to wax prior to immuno-
histochemistry.
Infection of cat 2 was identified via a retrospective
survey of oropharyngeal and/or conjunctival swabs
collected from 387 cats with respiratory signs that had
been submitted to the University of Glasgow Veteri-
nary Diagnostic Service (VDS) between March and July
2020 for routine pathogen testing.
Ethics approval
Ethical approval for this study was granted by the
University of Glasgow School of Veterinary Medicine
ethics committee (EA27/20). Permission was given for
the retrospective analysis of feline swabs submitted to
VDS for routine respiratory pathogen testing. Permis-
sion was also granted for a public appeal to practis-
ing veterinary surgeons via the veterinary record, to
solicit the submission of samples from suspect SARS-
CoV-2 cases.13 This appeal was in line with guidance
to veterinarians on the testing of animal samples for
SARS-CoV-2 from the Animal and Plant Health Agency,
issued on 13 May.14 This briefing note confirmed that
testing of animals for the purpose of clinical research
was permitted under appropriate ethical review.
On submitting samples to Scotland’s Rural College
(SRUC) Veterinary Services, veterinary practices agree
that any sample may be used to investigate new and
emerging diseases. Approval to test tissue samples
collected post-mortem from cat 1 in the study was
obtained from the owner by the primary veterinary
surgeon.
Respiratory pathogen screening
A retrospective screening programme was under-
taken, testing a set of 387 oropharyngeal swabs
that had been submitted to the University of
Glasgow VDS for routine testing for respiratory
pathogens (feline calicivirus (FCV), feline herpes
virus (FHV) and Chlamydia felis (C. felis). Samples
received in VTM were screened for FHV, FCV and
C. felis.
DNA extracts from VTM samples were tested for the
presence of FHV and C. felis using a multiplex quan-
titative polymerase chain reaction (qPCR) approach.
The assay incorporated published C. felis primers15
together with primers/probes for FHV and a feline
host control gene that were designed in-house. FCV
isolation was attempted using feline embryonic cells,
strain FEA,16 cultured in Dulbecco’s modified eagle’s
medium (DMEM) supplemented with 10% foetal
bovine serum, 2 mM L-glutamine, 1 mM sodium
pyruvate and 240 U mL−1 penicillin streptomycin
(Gibco, Life Technologies, UK). Cells were main-
tained at 37◦C in 5% CO2. Oropharyngeal swabs
were taken into DMEM, and the medium was inoc-
ulated onto FEA cells; FCV isolation was recognised
by the production of a characteristic cytopathic effect
as described previously.17 The remnants of these
samples were stored at 4◦C prior to RNA extraction
from each sample and testing for SARS-CoV-2 using
RT-qPCR.
Immunofluorescence staining of tissue
samples
Sections of 2–3 µm thickness of formalin-fixed and
paraffin-embedded (FFPE) lung and liver tissue
were cut with a microtome and mounted on glass
slides. After sodium-citrate pressure cooking, the
rabbit anti-nucleocapsid antibody (NovusBio, code:
NB100-56683SS, dilution 1:100) and an AlexaFluor-488
secondary antibody (ThermoFisher, code: A-11034)
as well as the ProLong Gold Antifade Mountant with
DAPI (ThermoFisher, code: P36935) were used. For
the detection of SARS CoV-2 specific RNA encoding S
by in situ hybridisation, the RNAscope 2.5 HD Reagent
Kit-RED (code: 322350, Advanced Cell Diagnostics)
and the probe V-nCoV2019-S (code: 848561, Advanced
Cell Diagnostics) were purchased and the protocol
was followed according to the manufacturer’s instruc-
tions. As positive controls (for immunofluorescence
and in situ hybridisation), FFPE-Vero cell pellets
experimentally infected with SARS CoV-2 were used
and mock infected FFPE-Vero cells served as negative
controls.
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RNA extraction from respiratory samples
and PCR amplification of SARS-CoV-2
genome
TRIzol Reagent (ThermoFisher Scientific, Paisley,
UK) was added to lyse the sample and ensure inac-
tivation of SARS-CoV-2, followed by organic solvent
extraction using chloroform: isoamyl alcohol. Sub-
sequent steps were performed using RNeasy Mini
Kits (Qiagen, Manchester, UK) as per the manufac-
turer’s instructions, with elution of the final RNA
sample in 55 µl nuclease-free water. One mock RNA
extraction was performed for every seven samples. All
samples were tested using two reverse transcriptase-
qPCR (RT-qPCR) assays: the 2019-nCoV_N1 assay
(https://www.fda.gov/media/134922/download)
and an Orf1ab assay (primerset-18, docu-
mented at https://tomeraltman.net/2020/03/03/
technical-problems-COVID-primers.html).
Primers and probe for the 2019-nCoV_N1 assay
were obtained ready-mixed from IDT (Leuven, Bel-
gium) and used at a final concentration of 500 nM
and 127.5 nM, respectively. Primers and probe for
the Orf1ab assay were synthesised by IDT and used
at a final concentration of 800 nM and 400 nM,
respectively. PCRs were performed in a final vol-
ume of 20 µl including NEB Luna Universal Probe
One-Step Reaction Mix and Enzyme Mix (both New
England Biolabs, Herts, UK) and 5 µl of RNA sam-
ple. Thermal cycling was performed on an Applied
Biosystems 7500 Fast PCR instrument running SDS
software v2.3 (ThermoFisher Scientific) using the
following conditions: 55◦C for 10 min and 95◦C for
1 min followed by 45 cycles of 95◦C for 10 s and
58◦C for 1 min. Four 10-fold dilutions of SARS-CoV-2
RNA standards, which were quantified by compar-
ison with plasmids containing the N1 sequences,
were tested in duplicate with each PCR assay. Neg-
ative controls included the mock RNA extractions
and at least two no-template controls per 96-well
plate.
Sequencing the feline SARS-CoV-2 genome
Following nucleic acid extraction, 5 µl of the
extract, corresponding to 81 genome copies, was
utilised to prepare a library, following a proto-
col developed by the ARTIC network, adapted
for Illumina sequencing. Briefly, the protocol
described in https://www.protocols.io/view/
ncov-2019-sequencing-protocol-v2-bdp7i5rn was
followed, until the amplicon generation stage, utilis-
ing the primer version 3. The resulting DNA amplicons
were cleaned using AMPURE beads (Beckman Coul-
ter) and libraries prepared using a DNA KAPA library
kit (Roche) following the manufacturer’s instructions.
Indexing was carried out with NEBNext multiplex
oligos (NEB), using seven cycles of PCR. Sequencing
was performed in a MiSeq system using a MiSeqV2
cartridge (500 cycles), resulting in 93.57% of reads with
Q score > 30. Reads were quality filtered with TrimGa-
lore (https://github.com/FelixKrueger/TrimGalore),
aligned to the Wuhan-Hu-1 reference strain (Gen-
Bank accession MN908947.3) using BWA18 fol-
lowed by primer trimming and consensus calling
with iVar.19 Negative controls processed in parallel
retrieved no viral mapped reads after primer trim-
ming. The created viral genome sequence for cat 2
was uploaded to GISAID with the accession number
EPI_ISL_536400.
The closest UK human SARS-CoV-2 sequence was
initially identified using the COG-UK cluster identifi-
cation tool civet (https://github.com/COG-UK/civet).
A maximum-likelihood phylogenetic tree of all unique
human SARS-CoV-2 sequences from the same county
as cat 2 (n = 324), along with the cat 2 genome,
the closest UK human sequence and the Wuhan-Hu-1
reference, was created using IQ-TREE20 with the GTR
substitution model (selected by IQ-Tree ModelFinder)
and 1000 bootstraps. Existing feline (n = 9; Bel-
gium, China, France, Spain, USA) and mink (n = 13;
Netherlands) SARS-CoV-2 genome sequences were
downloaded from the GISAID website (https://www.
gisaid.org) on 31 July 2020; a table of acknowledge-
ments for these sequences is listed in supplementary
materials.
RESULTS
Histopathological findings in cat 1 were
consistent with viral pneumonia
Cat 1 was a 4-month-old female Ragdoll kitten from a
household in which the owner developed symptoms
that were consistent with SARS-CoV-2 infection at the
end of March 2020, remaining symptomatic until 11
April 2020; the owner was not tested for SARS-CoV-2.
The kitten was presented to its veterinary surgeon
on 15 April 2020 with dyspnoea, and physical exam-
ination revealed signs of increased respiratory effort,
increased respiratory rate and harsh lung sounds.
Radiographic examination revealed an interstitial and
alveolar pattern. The cat’s condition deteriorated, and
it was euthanised on 22 April 2020. Histopathological
findings of the lung included a moderate to severe,
diffuse, alveolar damage with sloughed pneumo-
cytes, ruptured and thickened alveolar membranes,
multifocal intra-alveolar fibrin deposition, hyaline
membranes, pneumocyte type II hyperplasia, and the
presence of alveolar macrophages as well as thrombus
formation within capillaries, arteries and veins. Mild
to moderate amounts of inflammatory cells consisted
of multifocally to diffusely distributed lymphocytes
and macrophages. A few extravasated erythrocytes
were present within the alveolar spaces, which were
interpreted as mild haemorrhages, and moderate to
severe congestion, as well as mild alveolar oedema
was evident (Figure 1).
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F I G U R E 1 Section of lung of cat 1 stained with haematoxylin and eosin showing histopathological changes associated with viral
pneumonia at low magnification (a; bar, 2 mm) with the area within the box shown at high magnification (b; bar, 200 µm). A positive signal
for nucleocapsid protein (green signal) was detected within the cytoplasm of the bronchiolar epithelium (c; bar, 10 µm), and viral RNA (red
dots) of the spike gene was detectable in alveolar membranes (d; bar, 100 µm; haematoxylin counterstain)
F I G U R E 2 Timeline demonstrating the distribution of samples screened for SARS-CoV-2 and the testing strategy and sample collection
relative to the UK pandemic
SARS-CoV-2 antigen and RNA were
demonstrated within pneumonic lung
tissue
The presence of SARS CoV-2 antigen was demon-
strated following immunofluorescent staining of lung
sections incubated with an antibody recognising the
SARS-CoV-2 nucleocapsid (Figure 1). Antigen posi-
tive cells were detected in the bronchiolar epithe-
lium, whereas no positive cells were detected in liver
sections from the same cat. To rule out non-specific
immunofluorescent staining, in situ hybridisation was
performed, using a probe targeting the viral spike
gene. This demonstrated the presence of SARS-CoV-2
RNA in the lung; the positive signal was cell-associated
within the alveolar membranes, suggesting that type I
pneumocytes were infected (Figure 1). In contrast, nei-
ther viral protein nor RNA was detected in the liver.
Identification of SARS-CoV-2 RNA by
retrospective surveillance of feline
respiratory specimens
The sample collection for the retrospective screen-
ing of oropharyngeal swabs coincided with the period
when community transmission of SARS-CoV-2 was
widespread in the UK (Figure 2). Given the relatively
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low seroprevalence in humans (∼5%) at that time21
and, assuming that each cat sampled had an equal
chance of coming from a COVID-19 household, we
estimate that approximately 19 of 387 samples in the
collection came from cats belonging to COVID-19
affected households.
Among 387 oropharyngeal swabs tested, the sample
from one cat (subsequently designated as cat 2) tested
positive using both the 2019-nCoV-N1 and the Orf1ab
assays. All controls gave the expected results, and no
other sample run on the same plate was positive (35
feline samples), ruling out potential laboratory con-
tamination. The Ct values in the 2019-nCoV-N1 and
Orf1ab assays were 34 and 33.5, respectively, repre-
senting a mean copy number of 81 viral genomes per 5
µl of test sample. Any suggestion that cat 2 had been
contaminated with SARS-CoV-2 from the owner was
discounted as serum collected from the cat 8 weeks
after the initial sampling tested seropositive in a live
virus neutralisation assay conducted by an indepen-
dent laboratory,5 confirming productive infection of
cat 2.
The positive surveillance sample from cat 2 had
been collected from a 6-year-old female Siamese cat
that presented with bilateral yellow ocular discharge
as well as a serous nasal discharge. Conjunctival and
oropharyngeal swabs were collected from cat 2 on
15 May 2020 and sent to the University of Glasgow
VDS to be tested for respiratory pathogens. The swabs
tested positive for FHV DNA and negative by PCR for C.
felis, and neither FHV nor FCV was isolated following
attempted virus isolation on FEA cells.
One of the owners had symptoms consistent with
COVID-19 when cat 2 was presented to its veterinary
surgeon with clinical signs. The cat tested positive for
FHV DNA as well as SARS-CoV-2 RNA; the cat’s clinical
signs were consistent with FHV infection, and so the
SARS-CoV-2 infection might not have been related to
the clinical signs that the cat displayed at the time of
sampling. However, it is also possible that co-infection
with SARS-CoV-2 caused reactivation of FHV in this
cat.
Comparison of feline and human
SARS-CoV-2 genome sequences
To characterise cat 2′s viral genome, we performed
high-throughput sequencing on RNA derived from
the clinical specimen. The generated viral genome
sequence was 97.2% complete and contained 13 sin-
gle nucleotide polymorphisms (SNPs) when compared
with the original Wuhan_Hu-1 reference sequence.
Sequence data from the symptomatic owner were
not available; hence we compared the feline genome
with other human SARS-CoV-2 sequences, using data
from the COVID-19 Genomics UK (COG-UK) consor-
tium. The mutational hamming distance (ignoring Ns
and ambiguities) between the cat 2 viral genome and
all COG-UK human viral genomes available on 23
August 2020 revealed that the closest human SARS-
F I G U R E 3 Maximum likelihood phylogenetic tree of the cat 2
SARS-CoV-2 viral genome (blue) with all unique human
SARS-CoV-2 sequences from the same county as cat 2 (black). The
tree is rooted on the Wuhan-Hu-1 reference sequence MN908947
CoV-2 sequences from the UK differed from the feline
sequence by five SNPs (n = 141; Table 1); these human
sequences were distributed throughout the UK but
predominantly (88%)22 assigned to one lineage. The
closest sequences (n= 11) from the same county as cat
2 were an additional SNP away. Phylogenetic analyses
of these sequences reinforced the close relationship
between the cat 2 viral genome and human-derived
UK SARS-CoV-2 genomes (Figure 3). As we do not
have the owner’s virus sequence, we cannot deter-
mine whether the observed mutations in cat 2′s viral
genome arose in a human prior to transmission.
Table 1 details the SNPs observed in the cat 2 viral
genome and their frequency in the existing UK human
population and among existing feline SARS-CoV-2
sequences. Six of the 13 SNPs are widespread (>50%)
in the UK human population, and only three have
not been observed previously. It is most likely that the
three novel SNPs arose recently as evolutionary bot-
tlenecks during human-to-human transmission and
represent an unsampled cluster of human variants.
Given that no other feline or mink sequences con-
tained these mutations, there is little indication that
these correspond to a host species adaptation of the
virus.
Next, we examined all globally available feline SARS-
CoV-2 sequences from the GISAID database for evi-
dence of convergent mutations. Each of the six existing
complete feline viral genomes contained three SNPs in
common with cat 2 resulting in the D614G mutation in
Spike, the P323L mutation in nsp12 and a synonymous
mutation in nsp3. However, as these mutations are
widespread in the human population, it is likely that
they evolved in humans and are not associated with
feline adaptation. The existing feline viral sequences
were mutation distances of 0 (n = 4), 1 (n = 1), and 3
(n = 1) SNPs away from the closest human SARS-CoV-
2 sequence in their respective countries. It has been
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T A B L E 1 Details of the 13 SNPs observed in the cat 2 SARS-CoV-2 genome with respect to the original Wuhan-Hu-1 reference sequence,
at least eight of which occurred in humans. Rows highlighted in bold represent the five SNPs not observed in the closest human sequences in
the UK
Position Gene Mutation AA Change COG-UK Human % Feline %* Mink %
241 C > T non-coding 17.88 0 53.85
3037 ORF1ab/nsp3 C > T synonymous 82.22 100 53.85
3122 ORF1ab/nsp3 G > T D135Y 0.01 0 0
14408 ORF1ab/nsp12 C > T P323L 82.15 100 53.85
22330 S A > C synonymous 0 0 0
23403 S A > G D614G 82.37 100 53.85
25236 S T > C/T I1225T 0 0 0
25987 ORF3a G > T D199Y 0 0 0
27046 M C > T T175M 1.16 0 0
28312 N C > T synonymous 0.01 0 0
28881 N G > A R203K 52.88 40 0
28882 N G > A R203K 52.84 40 0
28883 N G > C G204R 52.84 40 0
*Three of the nine available feline sequences were less than 900 bases in length, and therefore feline percentages are calculated with respect to the sequences that
cover each genome position.
suggested that the D614G mutation in spike (shared
by the feline SARS-CoV-2 genomes) confers a fitness
advantage to the virus in humans,23,24 whether the
same mutation renders the virus more infectious for
cats remains to be established.
DISCUSSION
This is the first report of human-to-cat transmission of
SARS-CoV-2 in cats in the UK. Although the ongoing
SARS-CoV-2 pandemic is driven by human-to-human
transmission, concerns have been raised that other
species might have the potential to play a role by
becoming a new reservoir for the virus.25 Previously,
there have been sporadic reports of human-to-pet
transmission of SARS-CoV-2,3,4,6,26 as well as human-
to-wild felid5 and human-to-mink transmission.7
It is likely that such reports underestimate the true
frequency of human-to-animal transmission since
animal testing is limited and animals with subclinical
infections are rarely, if ever, tested. Reverse zoonotic
transmission represents a relatively low risk to animal
or public health in areas where human-to-human
transmission remains high. Nevertheless, as human-
to-human transmission eventually wanes, prospects
for transmission among animals become increasingly
important as a source for re-introductions to humans.
It is therefore important to improve our understand-
ing of whether exposed animals could play a role in
transmission. An analysis of the feline SARS-CoV-2
genome from cat 2 demonstrated a high degree of
sequence conservation with genomes derived from
infected humans. We examined all of the reported
feline SARS-CoV-2 sequence data and found no evi-
dence of adaptation in the feline sequences. It is
likely that all of the mutations in cat 2′s viral genome
were also present in the owner’s virus, although the
genome sequence of the owner’s virus was not avail-
able for comparison. Whether SARS-CoV-2-infected
cats could naturally transmit the virus to other ani-
mals, or back to humans, remains unknown. Given
the limited genetic variation observed to date among
SARS-CoV-2 genomes from animals and humans and
the evidence shown here that naturally infected cats
shed virus (or at least moderate concentrations of
viral RNA), it is highly likely that cat-derived viruses
could be transmitted to humans and to other animals.
Recent outbreaks in Dutch mink farms provided fur-
ther evidence of animal-to-animal transmission, and
mink-to-human transmission has also been reported.7
Further studies are urgently required to determine the
efficiency of animal-to-human transmission. It is
recognised that, for ethical reasons and limitations
on study design, it is unlikely that direct evidence
of cat-to-human transmission could be obtained.27
It would not be feasible to conduct an experiment
in which an uninfected person was exposed to an
infected cat to determine whether cat-to-human
transmission occurred. Therefore, it would be nec-
essary to rely on evidence from the field; this would
require that prior to exposure to an infected cat, a
person would have observed an effective quarantine
period, then they would have tested negative by PCR
and serological testing (to eliminate the potential for
undetected infection), and the person would have to
remain isolated from all potential sources of SARS-
CoV-2 other than the infected cat throughout the
quarantine period. However, it will be important to
investigate whether cat-to-human transmission is
possible, or likely, and to determine the duration of
virus shedding by infected cats and the level of con-
tact with humans that is required for transmission to
occur.
Cat 1 was euthanised because of the intractable pro-
gression of the dyspnoea in this kitten, whereas the
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milder clinical signs in cat 2 subsequently resolved.
RNA was extracted from the lung of cat 1 and tested
using only the 2019-nCoV-N1 RT-qPCR assay to con-
serve the lung sample, since the amount of tissue was
limited. The lung tissue tested positive, with the cycle
threshold (Ct) value of 39 reflecting a low viral load.
Illumina sequencing of the remaining RNA generated
a consensus sequence representing only 30% of the
genome, so sequence analyses were not performed.
Nevertheless, the negative controls included in the
sequencing run were negative, ruling out contamina-
tion and providing further confirmation of SARS-CoV-
2 infection in the lung tissue of cat 1. Nevertheless, it
is impossible to conclusively confirm that SARS-CoV-
2 infection caused the viral pneumonia observed in
this kitten, since the finding could have been inciden-
tal, and subclinical SARS-CoV-2 infections in cats from
COVID-19 households have been reported.28–30 Lung
tissue was not tested for other potential causes of the
pneumonia in this cat, e.g., FHV, FCV or Mycoplasma
species; intranuclear inclusion bodies consistent with
FHV infection were lacking.
Cat 2 tested positive for FHV and SARS-CoV-2; it
is possible that coinfection with SARS-CoV-2 had
led to reactivation of FHV in cat 2. Although no FHV
was isolated from oropharyngeal and conjunctival
swabs, FHV was detected by PCR, which is a more
sensitive technique that, in contrast to virus isolation,
is unaffected by sample degradation during transit.31
A second cat lived in the same household as cat 2, but
neither SARS-CoV-2 RNA nor SARS-CoV-2-specific
antibody responses were detected in the second cat,5
indicating that the virus was not transmitted between
these two animals that were living in the same house-
hold at the time of sampling. However, experimental
transmission studies have shown that SARS-CoV-2
replicates efficiently in cats, causes severe disease in
juvenile cats and can be transmitted from infected
to sentinel cats via droplets.8,10 The establishment of
cat-to-cat transmission cycles could conceivably be
suppressed or facilitated by local cat management
practices, including the frequency of indoor/outdoor
cats and the presence of feral cat colonies.
These two cases in the UK confirm previous find-
ings that cats can acquire infection in households
with SARS-CoV-2-infected humans. One owner in the
household to which cat 2 belonged tested positive
for SARS-CoV-2, but no-one from the household of
cat 1 was tested. However, one person in the latter
household had been symptomatic for approximately
2 weeks prior to cat 1 becoming dyspnoeic. Our
findings highlight the importance of co-ordinating
the testing of humans and animals within affected
households to monitor zoonotic transmission. The
retrospective screening of 387 respiratory samples
from cats led to the identification of a single cat
that tested positive for SARS-CoV-2. However, it is
unknown how many of these samples came from
cats living in COVID-19 affected households, and so
we cannot estimate the frequency of human-to-cat
transmission of SARS-CoV-2. Furthermore, the narrow
window for detecting SARS-CoV-2 RNA decreases the
likelihood of detecting zoonotic or reverse zoonotic
virus transmission. Even though animal-to-animal
transmission has been described ((8, 10), as well as a
possible animal-to-human transmission,12 it is pos-
sible that animal-to-animal transmission could be
greater under experimental conditions or in highly
contaminated, crowded environments, such as mink
farms. Variable rates of seropositivity among pet cats
have been reported. Firstly, it was reported that 15 of
102 (14.7%) cat sera collected following the outbreak
in Wuhan, China tested positive for antibodies that
recognised the receptor binding domain of SARS-
CoV-2 by ELISA, eleven of which (10.8%) also tested
positive for neutralising antibodies.32 Next, a sur-
vey of pet cats and dogs from confirmed COVID-19
households in France reported a high seroprevalence
of SARS-CoV-2 antibodies, ranging from 21 to 53%,
depending on the criteria used to define a positive
result33 and in a longitudinal study of 76 cats liv-
ing in COVID-19 households in Texas, US, eight of
17 cats tested positive for SARS-CoV-2 RNA or neu-
tralising antibodies (Hamer 2020). Also, in a study
conducted in Northern Italy, it was reported that 5.8%
of cats that were sampled at a time of frequent human
infection were seropositive.34 In contrast, a German
study suggested that human-to-cat transmission
might be relatively infrequent; only 0.69% (6/920) of
cats sampled between April and September 2020 for
haematological testing were seropositive.35 Similarly,
as few as 0.76% of cats presenting for routine veteri-
nary visits in Croatia tested positive for neutralising
antibodies.36 Furthermore, a study conducted in a vet-
erinary community of 20 students, two of whom tested
positive for COVID-19 and eleven of the remaining
18 displayed symptoms of COVID-19, demonstrated
that none of the nine cats living in the commu-
nity tested positive by RT-PCR, and none of them
developed antibodies.37 Therefore human-to-cat
transmission appears to be highly variable, perhaps
reflecting that transmission could be lower where
good hygiene is practised. Hence further surveil-
lance studies are needed to determine the preva-
lence of SARS-CoV-2 infection in cats, and whether
future infections of cats represent spillover events
from humans or are caused by sustained cat-to-cat
transmission.
These findings have potential implications for the
management of cats owned by people who develop
SARS-CoV-2 infection. Currently, there is no evidence
that domestic cats have played any role in the epi-
demiology of the COVID-19 pandemic, but a better
understanding of how efficiently virus is transmitted
from humans to cats will require cats in COVID-19
households to be monitored. The two cases of reverse
zoonotic infections that are reported here serve to
highlight the importance of a co-ordinated one health
approach between veterinary and public health organ-
isations.
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